anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chromoblastomycosis, an implantation mycosis, is a neglected tropical disease that causes decreased quality of life, stigma, and disability. The global burden of disease is unknown and data on disease epidemiology and outcomes are severely limited by a lack of access to needed diagnostic tools and therapeutics. The World Health Organization outlined targets for chromoblastomycosis in the Road Map for Neglected Tropical Diseases 2021-2030, but little progress has been made in initiating and implementing an effective control program globally. This lack of guiding policy and progress led to the recent formation of a Global Chromoblastomycosis Working Group which has developed a global chromoblastomycosis strategy. We describe this strategy, which outlines specific steps needed to improve technical progress, strategy and service delivery, and enablers. Clinicians, researchers, public and government officials, patients, and policy makers can align their time, expertise, and resources to improve the lives of communities affected by chromoblastomycosis through this strategy.
Aphasia is a communication disorder that affects processing of language at different levels (e.g., acoustic, phonological, semantic). Recording brain activity via Electroencephalography while people listen to a continuous story allows to analyze brain responses to acoustic and linguistic properties of speech. When the neural activity aligns with these speech properties, it is referred to as neural tracking. Even though measuring neural tracking of speech may present an interesting approach to studying aphasia in an ecologically valid way, it has not yet been investigated in individuals with stroke-induced aphasia. Here, we explored processing of acoustic and linguistic speech representations in individuals with aphasia in the chronic phase after stroke and age-matched healthy controls. We found decreased neural tracking of acoustic speech representations (envelope and envelope onsets) in individuals with aphasia. In addition, word surprisal displayed decreased amplitudes in individuals with aphasia around 195 ms over frontal electrodes, although this effect was not corrected for multiple comparisons. These results show that there is potential to capture language processing impairments in individuals with aphasia by measuring neural tracking of continuous speech. However, more research is needed to validate these results. Nonetheless, this exploratory study shows that neural tracking of naturalistic, continuous speech presents a powerful approach to studying aphasia.
Multicenter, single-blind, randomized, sham-controlled study of multi-polar radio-frequency (RF) and pulsed electro-magnetic field (PEMF) technologies for the treatment of symptoms associated with vulvovaginal atrophy. The study will enroll up to 106 subjects requesting treatment of symptoms of vulvovaginal atrophy (vaginal dryness, decreased lubrication during sexual activity, decreased elasticity, irritation, discomfort during intercourse and discomfort of the vaginal and vulvar tissues in general) in order to have 88 subjects complete the study. Subjects will be randomized in a 1:1 ratio to either multi-polar RF and PEMF technologies or sham treatment and will receive a total of three internal and external treatments with the Venus Fiore™ (MP)2 device at four-week intervals. Study treatment will be administered as per the parameter recommendations as set out in the Venus Fiore™ (MP)2 user manual. Subjects will be followed up at three and six months after their initial treatment. Analysis will be performed on all subjects who receive at least one treatment. Three- and six-month outcomes from the active arm will be compared to data from the sham arm.
Do not re-escalate the KADCYLA dose after a dose reduction is made.

If a planned dose is delayed or missed, administer as soon as possible; do not wait until the next planned cycle. Adjust the schedule of administration to maintain a 3-week interval between doses. Administer the infusion at the dose and rate the patient tolerated in the most recent infusion.

Slow or interrupt the infusion rate of KADCYLA if the patient develops an infusion-related reaction. Permanently discontinue KADCYLA for life-threatening infusion-related reactions [see Warnings and Precautions (5.5)].

Management of increased serum transaminases, hyperbilirubinemia, left ventricular dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy may require temporary interruption, dose reduction or treatment discontinuation of KADCYLA as per guidelines provided in Tables 1 and 2.
The invention discloses a traditional Chinese medicine veterinary drug ultra-micro powder for treating livestock and poultry immunosuppression disease and a preparation method thereof and solves problems of complex preparation technology, high cost and difficult clinical popularization and application in the prior art. The traditional Chinese medicine veterinary drug ultra-micro powder for treating livestock and poultry immunosuppression disease is a powdery product which is prepared from 5-55 parts of spatholobus suberctu, 5-35 parts of radix codonopsis and 5-40 parts of astragalus. The traditional Chinese medicine veterinary drug ultra-micro powder can enhance immune functions of livestock and poultry and is mainly used for enhancing the immune functions of livestock and poultry. All of the components of the traditional Chinese medicine veterinary drug ultra-micro powder are natural traditional Chinese medicine raw materials. The traditional Chinese medicine veterinary drug ultra-micro powder is easy to prepare, has effects of expelling evil and activating collaterals, clearing heat and removing toxic, and tonifying the middle and boosting qi. Meanwhile, the traditional Chinese medicine veterinary drug ultra-micro powder is wide in medicine source, is low in cost, is free of medicine residue and is slight in toxic and side effects. The invention belongs to ultra-micro crushing so that the medicine is easier to absorb.
Novel clock proteins BMAL2 (Brain-Muscle-Arnt-Like proteins 2) being important in the clock oscillation mechanism involving an optical input pathway and an output pathway; novel clock genes encoding these proteins; a method of screening a substance promoting or inhibiting a promoter transcriptional activity by using the same; etc.  cCLOCK, cPER2 and cBMAL1 genes are isolated by using chick pineal body which is a material suitable for studying circadian clock. Further, a cDNA encoding a novel clock protein cBMAL2, which showing a homology with cBMAL1, is isolated and its sequence is determined. Moreover, human, mouse and rat BMAL2 cDNAs are isolated respectively from a human embryo kidney cell line, mouse midbrain and rat early fibroblasts and the sequences of these cDNAs are determined. BMAL2 forms a hetero dimer with CLOCK, BMAL1, etc. It also forms a homo dimer.
Each participant in the intervention arm will receive one-on-one education on the purpose, benefits, and limitations of fentanyl test strip (FTS) testing and undergo a brief 20-minute FTS educational intervention (including a 2-3-minute video and hands-on demonstrations on how to use FTS). They will also receive a supply of 10 FTS upon enrollment and continued supply upon request throughout the 2-year follow up period. Each participant will also receive Opioid overdose education and a naloxone kit upon enrollment and re-supply of naloxone as needed throughout the 2-year follow up period.
Objective Drug fever is defined as a fever that temporally coincides with the start of a culprit drug and disappears after discontinuation of the drug. It is a common cause of nosocomial fever, which refers to a fever that develops beyond the first 48 h after hospital admission. However, the exact prevalence of drug fever among cases of nosocomial fever is unclear, as is the variation in prevalence depending on the clinical setting and most common causative drugs. Methods PubMed MEDLINE, Dialog EMBASE, Cochrane Central Register of Controlled Trials, World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov were systematically searched. Studies that reported the prevalence of drug fever in patients with nosocomial fever were included. Two of the four reviewers conducted independent assessments of the inclusion, data extraction, and quality. Pooled adjusted odds ratios were generated using a random-effects model and presented with 95% confidence intervals (CIs). Results Fifteen meta-analysis from 15 studies were included. Ten studies did not report the definition of drug fever or excluded febrile patients who were admitted to the hospital within 24-48 h. The pooled prevalence of drug fever among cases of nosocomial fever was 3.0% (95% CI, 0.6-6.8%), which was largely consistent across the settings, except for at oriental medicine hospital. Only four studies reported the causative agents, and antibiotics were the most frequently reported. Conclusions The prevalence of drug fever is low in patients with nosocomial fever. Clinicians should recognize that drug fever is a diagnosis of exclusion, even in cases of nosocomial fever.
Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
<P>PROBLEM TO BE SOLVED: To provide a skin tone concealer which can provide natural appearance and excellent transparency and is safe and to provide a cosmetic containing the same.  <P>SOLUTION: The skin tone concealer comprises a natural pigment-treated powder composed of a substrate powder and a natural pigment fixed thereon and having a maximum fluorescence emission peak in the range of 500-580 nm. The natural pigment is selected from among Curcumin, Carthamus yellow, and Gardenia yellow. The fixation of the natural pigment on the substrate powder can be achieved by bringing a solution of the pigment into contact with the substrate powder under agitation in a solution which does not dissolve the pigment to deposit the pigment on the surface of the powder and thereafter separating and drying the powder. The substrate powder is selected from among silica, talc, kaolin, a cellulose, a nylon, silk, and others.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A freeze-dried high-temp. resistant protecting agent for virus-type biologic products for veterinary medicine is prepared from several components through proportionally mixing. It features that each of its components is sterilized separately. For the components which can be sterilized under high temp., they are dissolved in distilled water according to the proportion of formulation and are sterilized at 116 deg.C for 30-40 min; and for those which do not resist the high temp., they are also dissolved in distilled water according the proportion of formulation and are filtered with 0.22 micron pore diameter filter membrane to remove bacteria; and then the two parts are mixed to obtain the freeze-dried high-temp. resistant, protecting agent. The mentioned two parts are added to the virus antigen liquid according to a proportion of 1:1 and after packaging, they are freeze-dried. The product can be stored at 2-8 deg.C for 24 months.
PURPOSE:To obtain a tacky agent for medical application, capable of efficiently absorbing a medicine percutaneously or through mucosa, not providing skin with irritation, applicable for many hours without causing peel and not damaging the keratin layer in peeling. CONSTITUTION:A tacky agent for medical application comprising (A) a blend polymer of a vinylpyrrolidone (co)polymer soluble in water and/or an alcohol and a (meth)acrylic acid (co)polymer, having preferably 1-30wt.%, especially 5-25wt.% content of (meth)acrylic acid copolymer, (B) a softening agent, a high-boiling compound such as preferably polyhydric alcohol or a derivative thereof as essential components and preferably further (C) a weakly basic organic carboxylic acid, preferably one providing 1% aqueous solution having pH7-9 in the ratio of 100 pts.wt. component A, 20-500 pts.wt. component B and 0.1-20 pts.wt. component C, preferably 50-300 pts.wt. component B and 1-10p pts.wt. component C.
Neuroinflammation, characterized by activation of glial cells, plays a critical role in central nervous system disorders. However, the precise mechanisms of neuroinflammation contributing to cognitive impairment remain elusive. Perineuronal nets (PNNs) are extracellular matrixes that envelop the cell bodies and dendrites of parvalbumin (PV)-positive interneurons and may be mediated by apolipoprotein E (ApoE) gene. To investigate whether disruption of PNNs associated with ApoE is implicated in neuroinflammation-induced cognitive impairment, we established a neuroinflammation model by administering lipopolysaccharides (LPS) at 0.5 mg/kg for 7 consecutive days. Cognitive function was assessed using the open field, Y-maze, and novel object recognition tests, and neural oscillations were also recorded. Furthermore, differentially expressed genes in microglia within the hippocampus were identified through single-cell RNA sequencing analysis. Overexpression of hyaluronan and proteoglycan link protein 1 (Hapln1) and ApoE knockdown were carried out through adeno-associated virus (AAV) injection to C57BL/6J mice and CX3CR1-CreERT2 mice, respectively. It was found that LPS-induced neuroinflammation impaired cognitive function by reducing PNNs and PV-positive interneurons' outputs, as well as disrupting gamma (γ) oscillations in the hippocampal CA1. Overexpression of Hapln1 was able to restore PV-positive interneurons and γ oscillations, ultimately alleviating the cognitive impairment. Mechanistically, LPS-triggered microglial activation leads to the phagocytosis of PNNs, a process influenced by ApoE. Notably, prevention of PNNs engulfment through targeting microglial ApoE in the CA1 improved cognitive impairment. Collectively, our study suggested that microglial phagocytosis of PNNs plays a key role in neuroinflammation-induced cognitive impairment, which is probably mediated by the ApoE.
The invention discloses a cancer cell/dendritic cell fusion tumor vaccine for expression of alpha1,3 galactosyl transferase and a preparation method thereof. According to the cancer cell/dendritic cell fusion tumor vaccine and its preparation method, a method for preparing fusion cell comprises a step of fusing cancer cell and dendritic cell to obtain fusion cell. The cancer cell is recombinant cell which contains alpha1,3 galactosyl transferase related gene and is used for expression of alpha1,3 galactosyl transferase. the alpha1,3 galactosyl transferase related gene is formed by connecting the alpha1,3 galactosyl transferase gene and GTTI. The alpha1,3 galactosyl transferase gene encodes protein with amino acid sequence being SEQ ID No.3. Nucleotide sequence of GTTI is from the 1st nucleotide to the 548th nucleotide in the SEQ ID No.4 of the sequence table.
Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
HYDROPHILIC, ELASTOMERIC, PRESSURE-SENSITIVE ADHESIVE  Abstract The present invention concerns a novel water-insoluble, hydrophilic, pressure-sensitive adhesive that has a number of unique characteristics including being elastomeric and ultraconformable.  This adhesive includes an irradiation cross-linked synthetic organic polymer having a three-dimensional matrix, and an adhesive plasticizer.  The plasticizer includes a substantially non-volatile elasticizer.  The adhesive is useful either as a coating on a supporting web-like substrate or as a self-supporting layer.  Also provided are various articles made using the adhesive such as a bandage or ostomy device, a method of making the adhesive, and methods of using the adhesive.     In one embodiment, the adhesive is electroconductive, and is useful for attaching an electrically conductive member of an electrode to a selected surface such as mammalian tissue.  Also provided is an electrode having a layer of this adhesive, and a method of adhering this electrode to mammalian tissue.
PURPOSE:An excellent uniform cosmetic having improved perfume retention and feeling of use, and comprising tasteless and odorless sclerogum which is a type of polysaccharide as a thickener. CONSTITUTION:Sclerogum (S) which is a polysaccharide obtained by cultivating a fungus belonging to the genus Sclerotium is homogemeously incorporated into a cosmetic, toilet soap or dentifrice. The sclerogum (S) is a tasteless or odorless substance harmless to the human body, and acts as a thickener due to the high viscosity resulting from water-solubility. The cosmetic thus obtained has a very high perfume retention, good storage stability and compatibity with the skin, e.g. adhesion to or spreading over the skin. The amount of S is about 0.01wt% in the case of a toothpaste.
After intubation, the plastic part of the 18G angioket is placed transnasally into both nostrils in the supine position of the patients who will undergo sphenopalatine ganglion block, with the head in 15-20° extension and is advanced until it contacts the posterior mucosa. After contact, withdraw 1 mm and apply 0.5% bupivacaine 2 ml by dropping into the postnasal space within 1 minute.
BACKGROUND: To date, although most thyroid carcinoma (THCA) achieves an excellent prognosis, some patients experience a rapid progression episode, even with differentiated THCA. Nodal metastasis is an unfavorable predictor. Exploring the underlying mechanism may bring a deep insight into THCA.
METHODS: A total of 108 THCA from Chinese patients with next-generation sequencing (NGS) were recruited. It was used to explore the gene alteration spectrum of THCA and identify gene alterations related to nodal metastasis in papillary thyroid carcinoma (PTC). The Cancer Genome Atlas THCA cohort was further studied to elucidate the relationship between specific gene alterations and tumor microenvironment. A pathway enrichment analysis was used to explore the underlying mechanism.
RESULTS: Gene alteration was frequent in THCA. BRAF, RET, POLE, ATM, and BRCA1 were the five most common altered genes. RET variation was positively related to nodal metastasis in PTC. RET variation is associated with immune cell infiltration levels, including CD8 naïve, CD4 T and CD8 T cells, etc. Moreover, Step 3 and Step 4 of the cancer immunity cycle (CIC) were activated, whereas Step 6 was suppressed in PTC with RET variation. A pathway enrichment analysis showed that RET variation was associated with several immune-related pathways.
CONCLUSION: RET variation is positively related to nodal metastasis in Chinese PTC, and anti-tumor immune response may play a role in nodal metastasis triggered by RET variation.
Lithium is concentrated within the thyroid and can inhibit thyroid synthesis and release which can lead to hypothyroidism. Where hypothyroidism exists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters, if any. Where hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used. Paradoxically, some cases of hyperthyroidism have been reported including Grave’s disease, toxic multinodular goiter and silent thyroiditis.

Monitor thyroid function before the initiation of treatment, at three months and every six to twelve months while treatment is ongoing. If serum thyroid tests warrant concern, monitoring should occur more frequently.
A tracking and management system for patients in a health care setting to improve efficiency and provide a visual office shown on a display device. A plurality of sensors are located throughout the health care office. The plurality of sensors can be located on patient data record holding devices, on chairs and medical equipment, and inside medical exam rooms. Each sensor communicates information to a central processing unit. Sensors located on the patient data record holding device detect the presence of an individual patient data record in the individual patient data record holder of the patient data record holding device and then transmit a signal to a central processing system. The central processing unit also receives information from an individual patient data record processing device.
Most occupational exposures to toxic chemicals occur in the context of complex mixtures, often in combination with varied diet, prescription drug use and disease. In principle, information-rich metabolic analyses provide an approach to study toxicologic consequences of such complex chemical interactions by revealing metabolic perturbations before irreversible injury occurs. This pilot study tests the feasibility of using GSH redox state and high resolution proton NMR spectroscopy (1H-NMR) to detect metabolic changes due to chemical interactions. The proposed model involves interaction of chemical exposure (2 doses of acetaminophen, APAP, 15 mg/kg) and 2 days of sulfur amino acid- (SAA-) free diet. 30% of APAP metabolism occurs through pathways dependent upon SAA metabolites and up to 50% of the RDA for SAA is needed to metabolize 2 doses of APAP. Both treatments are without toxicity in humans and both affect GSH homeostasis, which will be assessed in vivo by plasma measurements. Inter-individual variation will be minimized with each individual being his/her own control. Environmental and dietary influences will be controlled in a clinical research unit. Aim 1 is to determine whether SAA-free diet and APAP independently perturb GSH redox homeostasis. Aim 2 is to determine whether APAP intake interacts with SAA-free diet in affecting GSH redox state. Aim 3 is to use 1H-NMR spectroscopy to determine whether exposure to APAP and SAA-free diet interact in their effects on metabolic profile. The results will provide key data on the suitability and sensitivity of redox measurements and 1H-NMR spectroscopy for study of chemical interactions. This could provide a foundation for the use of perturbation of metabolic profile as a means to identify risks and consequences of complex chemical mixtures which would be especially relevant to occupational exposures in combination with therapeutic drugs and other health risk factors.
This arm uses the 'feedback' e-12HR. This version of the application allows to calculate the Mediterranean Diet Serving Score (MDSS) index; additionally, this version is designed to promote the Mediterranean diet.